PharmNovo attending LSX 3–4 May
PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.
"There is a huge need for safe and effective drugs for people suffering from neuropathic pain. Our drug candidate PN6047 has a novel mode of action that avoids the unwanted side effects of current treatments. I will be sharing the latest progress in the ongoing Phase I clinical trial and discuss the design of our upcoming Phase IIa studies planned for next year," says Per von Mentzer, CEO at PharmNovo.
Per von Mentzer is presenting on 4 May, at 10:45 at Showcase Biotech.
The LSX World Congress is Europe's leading partnering, strategy, and investment event for life science and executive leaders. To learn more about LSX and explore the agenda for the world congress, visit: https://lnkd.in/eZUDkZSv
PharmNovo attending LSX 3–4 May
PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.
"There is a huge need for safe and effective drugs for people suffering from neuropathic pain. Our drug candidate PN6047 has a novel mode of action that avoids the unwanted side effects of current treatments. I will be sharing the latest progress in the ongoing Phase I clinical trial and discuss the design of our upcoming Phase IIa studies planned for next year," says Per von Mentzer, CEO at PharmNovo.
Per von Mentzer is presenting on 4 May, at 10:45 at Showcase Biotech.
The LSX World Congress is Europe's leading partnering, strategy, and investment event for life science and executive leaders. To learn more about LSX and explore the agenda for the world congress, visit: https://lnkd.in/eZUDkZSv
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
